Last updated: October 6, 2026 Vaxcyte’s 31 valent pneumococcal vaccine VAX-31 met every prespecified primary immunogenicity endpoint in its pivotal adult Phase 3, OPUS-1, while
Last updated: October 5, 2026 Novartis licensed Abogen’s mRNA encoded T cell engager for $575 million upfront and up to $7.8 billion total, CSL paid
Last updated: October 2, 2026 Regeneron’s trevogrumab preserved up to 71.8% of the muscle volume otherwise lost on semaglutide over 52 weeks in the Phase
Last updated: October 1, 2026 Lilly’s EloraTZP, a combination of the amylin agonist eloralintide and tirzepatide, cut weight up to 23.3% over 48 weeks in
Last updated: September 30, 2026 Eli Lilly’s retatrutide cut body weight 20.8% and A1c 1.5 points at the top dose in the Phase 3 TRIUMPH-2
Last updated: September 29, 2026 Kodiak Sciences’ Zenkuda and KSI-501 both met their DAYBREAK Phase 3 primary endpoints in wet AMD, with 54% of Zenkuda
Last updated: September 28, 2026 At the IMS meeting, AbbVie’s etentamig posted a response rate of 74.0% versus 45.7% for standard therapy with median progression
Last updated: September 25, 2026 GRAL closed at $125.21 on September 24, up 15.4% from its last trade in the first session after its favorable
Grail’s Galleri Won Its FDA Panel 7 to 2 on Benefit Risk With a 6 to 4 Effectiveness Split as Roche’s Sefaxersen Hit in IgA
Last updated: September 23, 2026 The FDA’s Molecular and Clinical Genetics Panel meets today to vote on whether Grail’s Galleri multi cancer test is safe
